Onconetix 8-K: Leadership Changes & Compensation Arrangements
Ticker: ONCO · Form: 8-K · Filed: Jan 12, 2024 · CIK: 1782107
| Field | Detail |
|---|---|
| Company | Onconetix, INC. (ONCO) |
| Form Type | 8-K |
| Filed Date | Jan 12, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.00001, $158,333, $40,000 |
| Sentiment | mixed |
Complexity: simple
Sentiment: mixed
Topics: leadership-change, executive-compensation, corporate-governance
TL;DR
**Onconetix just announced leadership changes and new compensation plans, watch for strategic shifts.**
AI Summary
On January 10, 2024, Onconetix, Inc. filed an 8-K to report the departure of directors or certain officers and the election of new directors or appointment of certain officers, along with compensatory arrangements. This filing indicates potential changes in leadership and executive compensation, which could impact the company's strategic direction and financial performance. Investors should monitor these changes as they may signal shifts in corporate governance or operational focus.
Why It Matters
Changes in leadership and executive compensation can significantly influence a company's future strategy, operational efficiency, and ultimately, its stock performance. New leadership might bring fresh perspectives or a different risk appetite.
Risk Assessment
Risk Level: medium — Changes in leadership can introduce uncertainty regarding future company direction and performance, making it a medium risk event.
Analyst Insight
Investors should closely monitor subsequent filings or press releases from Onconetix, Inc. for details on the specific individuals involved in the leadership changes and the nature of the compensatory arrangements. This information will provide clarity on the strategic implications and potential impact on the company's financial health.
Key Players & Entities
- Onconetix, Inc. (company) — the registrant filing the 8-K
- January 10, 2024 (date) — date of earliest event reported in the 8-K
- Delaware (company) — state of incorporation for Onconetix, Inc.
- 001-41294 (company) — Commission File Number for Onconetix, Inc.
- 201 E. Fifth Street, Suite 1900, Cincinnati, Ohio, 45202 (company) — address of Principal Executive Offices for Onconetix, Inc.
FAQ
What was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on January 10, 2024.
What specific items are being reported in this 8-K by Onconetix, Inc.?
Onconetix, Inc. is reporting on the 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers' and 'Financial Statements and Exhibits'.
What is the business address of Onconetix, Inc. as stated in the filing?
The business address of Onconetix, Inc. is 201 E. Fifth Street, Suite 1900, Cincinnati, Ohio, 45202.
What is the telephone number for Onconetix, Inc.?
The telephone number for Onconetix, Inc. is (513) 620-4101.
What was the former name of Onconetix, Inc. before its most recent name change?
The former name of Onconetix, Inc. before its most recent name change on April 24, 2023, was Blue Water Biotech, Inc.
Filing Stats: 695 words · 3 min read · ~2 pages · Grade level 10.3 · Accepted 2024-01-12 16:51:21
Key Financial Figures
- $0.00001 — ch Registered Common Stock, par value $0.00001 per share ONCO The Nasdaq Stock Mar
- $158,333 — receive a one-time severance payment of $158,333 (the "Release"). The foregoing descript
- $40,000 — e officer. Mr. Sapirstein shall receive $40,000 per month as compensation for his servi
Filing Documents
- ea191591-8k_onconetix.htm (8-K) — 30KB
- ea191591ex99-1_onconetix.htm (EX-99.1) — 27KB
- 0001213900-24-003413.txt ( ) — 239KB
- onco-20240110.xsd (EX-101.SCH) — 3KB
- onco-20240110_lab.xml (EX-101.LAB) — 33KB
- onco-20240110_pre.xml (EX-101.PRE) — 22KB
- ea191591-8k_onconetix_htm.xml (XML) — 3KB
02
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Effective as of January 10, 2024, Dr. Neil Campbell resigned as President and Chief Executive Officer and a member of the Board of Directors (the "Board") of Onconetix, Inc. (the "Company"). Dr. Campbell's resignation is not the result of any disagreement with the Company relating to the Company's operations, policies or practices. The Company entered into a Release of Claims with Dr. Campbell, pursuant to which Dr. Campbell will receive a one-time severance payment of $158,333 (the "Release"). The foregoing description of the Release is qualified in its entirety by reference to the full text of the Release, a copy of which is filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. On January 12, 2024, the Board appointed Dr. Ralph Schiess, the Company's Chief Science Officer, to serve as the Company's Interim Chief Executive Officer. As Interim Chief Executive Officer, Dr. Schiess shall have general supervision and direction of the business and affairs of the Company. The biographical information for Dr. Schiess disclosed in the Company's Current Report on Form 8-K filed with the SEC on December 21, 2023 is incorporated herein by reference. No family relationships exist between Dr. Schiess and any other directors or executive officers of the Company. There are no transactions to which the Company is or was a participant and in which either Dr. Schiess has a material interest subject to disclosure under Item 404(a) of Regulation S-K. Also on January 12, 2024, the Board appointed James Sapirstein, the current Non-Executive Chairman of the Board, to serve as Lead Independent Director pending the Board's appointment of a permanent chief executive officer. Mr. Sapirstein shall receive $40,000 per month as compensation for his services as Lead Independent Director.
01. Financial Statements
Item 9.01. Financial Statements and Exhibits. (d) Exhibits 99.1 Release, dated January 10, 2024, between the Company and Dr. Neil Campbell. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Onconetix, Inc. Date: January 12, 2024 By: /s/ Bruce Harmon Bruce Harmon Chief Financial Officer 2